Names | |
---|---|
IUPAC name
(2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}phenyl)glycine
| |
Systematic IUPAC name
(2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}anilino)acetate | |
Other names
ON-01910
| |
Identifiers | |
CAS Number
|
|
3D model (JSmol)
|
|
ChEBI |
|
ChEMBL |
|
ChemSpider |
|
IUPHAR/BPS
|
|
KEGG |
|
PubChem CID
|
|
UNII |
|
CompTox Dashboard (EPA)
|
|
InChI
| |
SMILES
| |
Properties | |
Chemical formula
|
C21H25NO8S |
Molar mass | 451.49 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
|
Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.[2] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.[3]
Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.